These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 25618448)

  • 1. Copeptin (C-terminal pro arginine-vasopressin) is an independent long-term prognostic marker in heart failure with reduced ejection fraction.
    Pozsonyi Z; Förhécz Z; Gombos T; Karádi I; Jánoskuti L; Prohászka Z
    Heart Lung Circ; 2015 Apr; 24(4):359-67. PubMed ID: 25618448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.
    Neuhold S; Huelsmann M; Strunk G; Stoiser B; Struck J; Morgenthaler NG; Bergmann A; Moertl D; Berger R; Pacher R
    J Am Coll Cardiol; 2008 Jul; 52(4):266-72. PubMed ID: 18634981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study.
    Voors AA; von Haehling S; Anker SD; Hillege HL; Struck J; Hartmann O; Bergmann A; Squire I; van Veldhuisen DJ; Dickstein K;
    Eur Heart J; 2009 May; 30(10):1187-94. PubMed ID: 19346228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure.
    Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
    JAMA; 2011 May; 305(20):2088-95. PubMed ID: 21610241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure.
    Tentzeris I; Jarai R; Farhan S; Perkmann T; Schwarz MA; Jakl G; Wojta J; Huber K
    Eur J Heart Fail; 2011 Jul; 13(7):726-33. PubMed ID: 21616953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Copeptin as a biomarker in heart failure.
    Balling L; Gustafsson F
    Biomark Med; 2014; 8(6):841-54. PubMed ID: 25224940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study.
    Maisel A; Xue Y; Shah K; Mueller C; Nowak R; Peacock WF; Ponikowski P; Mockel M; Hogan C; Wu AH; Richards M; Clopton P; Filippatos GS; Di Somma S; Anand IS; Ng L; Daniels LB; Neath SX; Christenson R; Potocki M; McCord J; Terracciano G; Kremastinos D; Hartmann O; von Haehling S; Bergmann A; Morgenthaler NG; Anker SD
    Circ Heart Fail; 2011 Sep; 4(5):613-20. PubMed ID: 21765124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure.
    Gegenhuber A; Struck J; Dieplinger B; Poelz W; Pacher R; Morgenthaler NG; Bergmann A; Haltmayer M; Mueller T
    J Card Fail; 2007 Feb; 13(1):42-9. PubMed ID: 17339002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of hyponatremia and elevated copeptin with death and need for transplantation in ambulatory patients with chronic heart failure.
    Miller WL; Grill DE; Struck J; Jaffe AS
    Am J Cardiol; 2013 Mar; 111(6):880-5. PubMed ID: 23276468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses.
    Balling L; Kistorp C; Schou M; Egstrup M; Gustafsson I; Goetze JP; Hildebrandt P; Gustafsson F
    J Card Fail; 2012 May; 18(5):351-8. PubMed ID: 22555263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast Growth Factor 23 Is an Independent and Specific Predictor of Mortality in Patients With Heart Failure and Reduced Ejection Fraction.
    Koller L; Kleber ME; Brandenburg VM; Goliasch G; Richter B; Sulzgruber P; Scharnagl H; Silbernagel G; Grammer TB; Delgado G; Tomaschitz A; Pilz S; Berger R; Mörtl D; Hülsmann M; Pacher R; März W; Niessner A
    Circ Heart Fail; 2015 Nov; 8(6):1059-67. PubMed ID: 26273098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of N-terminal pro C-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction.
    Lok DJ; Klip IT; Voors AA; Lok SI; Bruggink-André de la Porte PW; Hillege HL; Jaarsma T; van Veldhuisen DJ; van der Meer P
    Eur J Heart Fail; 2014 Sep; 16(9):958-66. PubMed ID: 25082741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of a multi-marker risk score for predicting cause-specific mortality at three years in older patients with heart failure and reduced ejection fraction.
    Bjurman C; Holmström A; Petzold M; Hammarsten O; Fu ML
    Cardiol J; 2015; 22(1):31-6. PubMed ID: 24526512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical application value of the plasma copeptin level in the assessment of heart failure with reduced left ventricular ejection fraction: A cross-sectional study.
    Xu L; Liu X; Wu S; Gai L
    Medicine (Baltimore); 2018 Sep; 97(39):e12610. PubMed ID: 30278578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction.
    Kelly D; Squire IB; Khan SQ; Quinn P; Struck J; Morgenthaler NG; Davies JE; Ng LL
    J Card Fail; 2008 Nov; 14(9):739-45. PubMed ID: 18995178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the association of serum sodium with mortality in patients with type 2 diabetes explained by copeptin or NT-proBNP? (ZODIAC-46).
    Riphagen IJ; Logtenberg SJ; Groenier KH; van Hateren KJ; Landman GW; Struck J; Navis G; Kootstra-Ros JE; Kema IP; Bilo HJ; Kleefstra N; Bakker SJ
    Atherosclerosis; 2015 Sep; 242(1):179-85. PubMed ID: 26201002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.
    de Antonio M; Lupon J; Galan A; Vila J; Urrutia A; Bayes-Genis A
    Am Heart J; 2012 May; 163(5):821-8. PubMed ID: 22607860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe mitral regurgitation is associated with increased copeptin levels in heart failure with reduced ejection fraction.
    Kılıcgedık A; Eroglu E; Kahvecı G; Isgandarov K; Acar E; Ozturk S; Zehir R; Kulahcıoglu S; Toprak C; Yaman A; Izgı IA; Kirma C
    Kardiol Pol; 2017; 75(12):1307-1314. PubMed ID: 28715068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic performance of serial in-hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the MOLITOR study.
    Düngen HD; Tscholl V; Obradovic D; Radenovic S; Matic D; Musial Bright L; Tahirovic E; Marx A; Inkrot S; Hashemi D; Veskovic J; Apostolovic S; von Haehling S; Doehner W; Cvetinovic N; Lainscak M; Pieske B; Edelmann F; Trippel T; Loncar G
    ESC Heart Fail; 2018 Apr; 5(2):288-296. PubMed ID: 29476612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.